Janus Henderson Group
COCH icon

Janus Henderson Group’s Envoy Medical COCH Stock Holding History

Janus Henderson Group’s Portfolio COCH Stock Details COCH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-277,972
Closed -$2.79M – 2694
2022
Q4 		$2.79M Buy
277,972
+149,778
+117% +$1.49M ﹤0.01% 1011
2022
Q3 		$1.26M Buy
+128,194
New +$1.26M ﹤0.01% 1527

Other funds holding COCH

AMC
Atlas Merchant Capital New York $789K AUM 60.67% 1-Year Est. Return
SIM
Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return
MC
Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Janus Henderson Group's COCH Position: Q1 2023 in Review

Janus Henderson Group sold out of Envoy Medical (COCH) in Q1 2023, closing a stake of 277,972 shares — an estimated $2.79M sold.

Janus Henderson Group first reported a position in COCH in Q3 2022 and held it in 2 quarters. The position peaked at $2.79M in Q4 2022. 24 funds tracked by Wall St. Rank hold COCH as of Q1 2023.

  • Janus Henderson Group reported no remaining Envoy Medical position as of Q1 2023 after selling out during the quarter.
  • Janus Henderson Group sold 277,972 Envoy Medical shares in Q1 2023, an estimated $2.79M.
  • Janus Henderson Group first reported a position in Envoy Medical in Q3 2022 and held it in 2 quarters.
  • Janus Henderson Group's Envoy Medical position peaked at $2.79M in Q4 2022.
  • 24 funds tracked by Wall St. Rank held Envoy Medical as of Q1 2023.

Based on Janus Henderson Group's 13F filing for Q1 2023, filed 15 May 2023.